At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Merck emphasized the broader significance of the findings
Subscribe To Our Newsletter & Stay Updated
